Key Drivers
- Strong Liquidity
- Persistent Cash Burn
- High Leverage
AIAI Summary
VSTM has evolved into a commercial-plus-pipeline story, but investors should treat the October 14 VS-7375 data as the decisive catalyst: AVMAPKI's strong early sales and ~90% gross margin validate demand, yet they do not currently cover the company's sizable cash burn or eliminate dilution risk. Maintain a catalyst-driven stance only if VS-7375 shows clearly differentiated, durable KRAS G12D activity and AVMAPKI growth begins materially extending runway.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Cash Burn
- •High Leverage
VSTM has ample near-term liquidity but remains high risk due to persistent losses, heavy cash burn, leverage, and an elevated valuation unsupported by profitability.
Price Behavior
Key Price Behavior Insights:
- •Positive monthly trend
- •Fading peak momentum
- •Critical support zone
VSTM remains in a positive last-month trend but faces fading momentum; hold above $7.20–$7.35 for bullish continuation, while a break below would signal weakness.
Declined from the $8.20 peak to $7.44, signaling short-term momentum loss
Sentiment & News
Key News Insights:
- •Launch Revenue Growth
- •VS-7375 Catalyst
- •Positive Sentiment
Verastem's strong AVMAPKI FAKZYNJA launch revenue, advancing VS-7375 data catalysts, and favorable sentiment support a positive near-term outlook.
Continued commercial execution and upcoming clinical updates could strengthen VSTM's valuation momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings